B+
Bull case
25%
Probability
Target price
$5.60
+15.9% vs current
MRVI
Maravai LifesciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$4.30
-11.0% vs current
B-
Bear case
25%
Probability
Target price
$3.10
-35.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+38.1
Score
AI commentary
Primary-source earnings evidence turned more constructive on May 7, 2026, and the market reaction was positive: using the packet anchor of $3.94 on 2026-05-07 and a live quote around $4.85 on 2026-05-09, shares were up roughly 23% post-print. Even so, this still looks like a cautious post-earnings monitoring setup because analyst revision evidence is not yet well populated, target data are sparse/stale, and the quality of the rerating depends on whether investors underwrite durable base-business growth rather than a quarter flattered by COVID-linked CleanCap volume.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07eventQ1 2026 beat with raised full-year guidance [#8-K-2026-05-07]High impact
Maravai reported Q1 2026 revenue of $65.8 million, up 40.5% year over year, returned to positive free cash flow of $4.2 million, and raised FY2026 revenue guidance to $205 million-$215 million from $200 million-$210 million while lifting adjusted EBITDA guidance to $30 million-$32 million from $18 million-$20 million. Management tied the upside to stronger TriLink demand and operating-efficiency gains. [#8-K-2026-05-07]
2026-05-31catalystPost-earnings estimate and target refresh windowMedium impact
The stock moved sharply higher after earnings, but post-print analyst revision evidence remains thin as of May 9, 2026. With sparse target coverage and the packet median target near $4.33 versus a live price around $4.85, follow-through likely depends on whether delayed analyst revisions validate the guidance raise rather than treat the quarter as mostly COVID-order aided.
2026-12-31catalystFY2026 execution on TriLink base growth, cash flow, and deleveragingHigh impact
Beyond the headline boost from high-volume CleanCap orders, the more durable thesis is whether TriLink base non-COVID revenue growth, higher-margin mix, positive free cash flow, and debt reduction can persist through 2026. The 10-Q showed cash of $165.9 million, long-term debt of $235.6 million net of current portion, and a $51.4 million voluntary term-loan repayment in Q1, so sustained execution matters for a cleaner rerating. [#10-Q-2026-05-08]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology